Taking a Look at Tau-Targeting Therapies for Alzheimer’s Disease

November 2, 2021Henry Peck

Since the discovery of Alzheimer’s disease, many potential pathological mechanisms of the disease have been proposed and explored. The growing understanding of the pathogenesis of Alzheimer’s disease has given rise to many potential avenues for treating the disease. 

Neuropathological hallmarks of Alzheimer’s disease consist of positive lesions that include tau hyperphosphorylation and neurofibrillary tangles, beta-amyloid plaques, cerebral amyloid angiopathy, and glial responses, and negative lesions that include neuronal and synaptic loss. Most commonly, Alzheimer’s disease is characterized by beta-amyloid plaques and neurofibrillary tangles resulting from abnormal tau hyperphosphorylation.

Similar to how Aducanumab (Aduhelm) aims to target and reduce beta-amyloid plaques in the brain, future treatments may include tau-targeting therapies for Alzheimer’s disease.

Below, we explore tau pathology in Alzheimer’s disease, potential tau-targeting therapies, and tau’s role in the detection of Alzheimer’s disease.

Tau Pathology in Alzheimer’s Disease

Tau, a microtubule-associated protein, is normally located on the axon and plays an important role in the brain. Tau physiologically facilitates axonal transport by binding and stabilizing microtubules that help guide nutrients and molecules from the cell body to the axon and dendrites. Microtubules provide structural stability as well as a physical scaffold for transporting vesicles, mitochondria, and chemicals to the synaptic junction.

In those who develop Alzheimer’s disease, tau becomes altered and accumulates, forming neurofibrillary tangles within nerve cells up to 15 years before symptom onset. This alteration involves the translocation of tau to some somatodendritic compartments and the hyperphosphorylation, misfolding, and aggregation of tau. Neurofibrillary tangles are intraneuronal aggregates of this hyperphosphorylated, misfolded tau and block the neuron’s transport system, harming the synaptic communication between neurons.

Exploring Potential Tau-Targeting Therapies for Alzheimer’s

Tau is a newly understood component in the pathophysiological biomarker landscape, and potential concepts for tau-targeting therapies for Alzheimer’s are still being researched to inform future drug and therapy discoveries. 

It is believed that tau pathology better correlates with the decline of neurocognitive impairments that occur in Alzheimer’s disease compared to beta-amyloid lesions. The pattern of tau aggregation in the brain appears to mirror the progressive loss of function in brain regions observed in those with Alzheimer’s. This suggests that once the clinical onset of symptoms is evident, tau-targeting therapies for Alzheimer’s disease may be more effective than those that aim to clear or reduce beta-amyloid plaques.

Currently, the abnormal hyperphosphorylation of tau is the most compelling cause of the dysfunctional, toxic tau that ultimately results in progressive neurodegeneration. Potential approaches to blocking tau-mediated toxicity include the following:

  • Directly inhibiting the pathological tau aggregation
  • Inhibiting tau after translational modifications and before pathological tau aggregation
  • Inhibiting tau propagation
  • Stabilizing microtubules

The Role of Tau in the Detection of Alzheimer’s Disease

While the discovery of tau pathologies and growing understanding of their significance to the disease provides new and promising avenues for potential tau-targeting therapies for Alzheimer’s disease, they are challenging to use to detect Alzheimer’s. Similar to beta-amyloid plaques, tau can be detected with tau positron emission tomography brain imaging technology and can serve as a biomarker in cerebrospinal fluid analyses. However, they do not assess the impact of Alzheimer’s disease on an individual's ability to complete complex Activities of Daily Living (ADLs), meaning they are not ecologically valid. Furthermore, such diagnostic tools lack cost efficiency.

Regardless of the pathology present in someone with Alzheimer’s, their ability to complete ADLs will be impacted. Understanding at a highly granular level how an individual’s ADLs are changing is perhaps the most compelling method for Alzheimer’s disease diagnostics and monitoring.

Pioneering Precision Neurology to Drive Early Alzheimer’s Disease Diagnosis and Monitoring

Altoida is developing the world’s first Precision Neurology platform and app-based medical device to provide a more comprehensive method for assessing and monitoring brain health in the most accurate, effective, and cost-efficient way possible. 

By completing a series of highly immersive and interactive augmented reality and motor activities on a smartphone or tablet, Altoida’s device provides robust measurements of brain health across 13 unique neurocognitive domains:

  • Perceptual-motor coordination
  • Complex attention
  • Inhibition 
  • Flexibility
  • Visual perception
  • Planning
  • Prospective memory
  • Spatial memory
  • Cognitive processing speed
  • Eye movement
  • Speech and articulation 
  • Fine motor coordination
  • Gait

Our device measures and analyzes nearly 800 cognitive and functional digital biomarkers that map to the 13 neurocognitive domains and have been proven to be clinically significant through over 20 years of rigorous scientific research. 

Combined with our innovative artificial intelligence, this method will pioneer fully digital predictive neurological disease diagnosis. After our recent Breakthrough Device designation by the FDA, Altoida’s technology will provide individuals with a predictive score that will enable a highly accurate prediction of whether an individual aged 55 and older will or will not convert from Mild Cognitive Impairment to Alzheimer’s disease within 12 months.

To learn more about Altoida’s Precision Neurology platform and device or tau-targeting therapies for Alzheimer’s disease, contact us today.

Contact Us

At Altoida, we use digital biomarkers to radically change the method of assessing brain health and cognitive diseases. After nearly two decades of research, we are developing a platform and device to measure and analyze cognitive biomarkers associated with cognitive impairment to evaluate perceptual and memory function.
Contact Us

Contact Us

80 M Street SE, Suite 100 Washington, DC 20003 USA 

CONTACT@ALTOIDA.COM

Follow Us

Policy

By visiting our Website and/or using the Services in any manner, you acknowledge that you accept the practices and policies outlined in our Privacy Policy.
@ Altoida 2021
chevron-down